(Q43564785)

24 November 2017

title

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia (English)

1 reference

24 November 2017

0 references

1 reference

Knapp HH

1

1 reference

24 November 2017

Schrott H

2

1 reference

24 November 2017

Ma P

3

1 reference

24 November 2017

Knopp R

4

1 reference

24 November 2017

Chin B

5

1 reference

24 November 2017

Gaziano JM

6

1 reference

24 November 2017

Donovan JM

7

1 reference

24 November 2017

Burke SK

8

1 reference

24 November 2017

Davidson MH

9

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Medicine

24 November 2017

published in

1 reference

24 November 2017

volume

110

1 reference

24 November 2017

issue

5

1 reference

24 November 2017

page(s)

352-360

1 reference

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Range of serum cholesterol values in the population developing coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Role of the enterohepatic circulation of bile salts in lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900638-6

10.1016/S0002-9343(01)00638-6

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference